{"id":25466,"date":"2026-02-23T05:16:38","date_gmt":"2026-02-23T10:16:38","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/danish-drugmakers-weight-loss-medication-underperforms-against-competitor\/"},"modified":"2026-02-23T05:16:38","modified_gmt":"2026-02-23T10:16:38","slug":"danish-drugmakers-weight-loss-medication-underperforms-against-competitor","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/danish-drugmakers-weight-loss-medication-underperforms-against-competitor\/","title":{"rendered":"Danish Drugmaker’s Weight Loss Medication Underperforms Against Competitor"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

A major pharmaceutical company announced disappointing results Monday for its experimental weight loss medication, dealing a significant blow in the competitive obesity drug marketplace.<\/p>

Danish drugmaker Novo Nordisk revealed that its developing treatment CagriSema performed worse than competitor Eli Lilly’s tirzepatide when tested directly against each other in clinical studies.<\/p>

The clinical study was structured to demonstrate that CagriSema could match tirzepatide’s effectiveness in helping patients lose weight, but the experimental drug failed to reach that benchmark, according to company officials.<\/p>

This disappointing outcome represents a major challenge for Novo Nordisk as it attempts to reclaim its early leadership position in the profitable weight management pharmaceutical sector, where consumers increasingly demand more powerful treatments.<\/p>

Following the announcement, Novo Nordisk’s stock value dropped 11% by mid-morning European trading.<\/p>

According to the company’s data, CagriSema helped patients achieve a 23% reduction in body weight during the 84-week study period, while Eli Lilly’s tirzepatide produced a 25.5% weight reduction in the same trial.<\/p>

These findings indicate that Novo’s developing medication was less successful than Eli Lilly’s existing treatment, which consumers can already purchase under the brand names Zepbound and Mounjaro.<\/p>

Company officials noted that additional studies are currently investigating CagriSema’s complete weight reduction capabilities, including testing stronger dosage combinations.<\/p>

Meanwhile, Lilly’s stock price increased 4% to $1,049.94 during pre-market trading in the United States.<\/p>","protected":false},"excerpt":{"rendered":"

Novo Nordisk’s experimental weight loss drug CagriSema showed lower effectiveness than Eli Lilly’s tirzepatide in clinical trials. The Danish company’s stock dropped 11% following the disappointing results in the competitive obesity medication market.<\/p>\n","protected":false},"author":4,"featured_media":25465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[834],"tags":[],"class_list":["post-25466","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771841797556.jpg?fit=450%2C322&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-6CK","jetpack-related-posts":[{"id":25514,"url":"https:\/\/tvdelmarva.com\/wp\/novo-nordisk-stock-crashes-15-after-weight-loss-drug-trial-disappoints\/","url_meta":{"origin":25466,"position":0},"title":"Novo Nordisk Stock Crashes 15% After Weight Loss Drug Trial Disappoints","author":"Admin","date":"February 23, 2026","format":false,"excerpt":"Danish pharmaceutical giant Novo Nordisk saw its stock price plummet more than 15% Monday after announcing its experimental obesity medication CagriSema failed to match competitor Eli Lilly's drug in clinical trials. The disappointing results erased all stock gains the company had made since launching its popular weight loss drug Wegovy.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771849090565.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":26176,"url":"https:\/\/tvdelmarva.com\/wp\/major-bank-dramatically-cuts-revenue-projections-for-obesity-drug-after-poor-trial-data\/","url_meta":{"origin":25466,"position":1},"title":"Major Bank Dramatically Cuts Revenue Projections for Obesity Drug After Poor Trial Data","author":"Admin","date":"February 24, 2026","format":false,"excerpt":"Financial analysts at Barclays have dramatically reduced their revenue expectations for a new obesity medication from Novo Nordisk by more than 80% following disappointing clinical trial results. The drug failed to outperform a competing treatment from Eli Lilly, dealing a significant blow to the Danish pharmaceutical company's market position.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771924617171.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771924617171.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771924617171.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771924617171.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771924617171.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":25613,"url":"https:\/\/tvdelmarva.com\/wp\/danish-drugmakers-weight-loss-drug-falls-short-against-rival-in-clinical-trial\/","url_meta":{"origin":25466,"position":2},"title":"Danish Drugmaker’s Weight-Loss Drug Falls Short Against Rival in Clinical Trial","author":"Admin","date":"February 23, 2026","format":false,"excerpt":"Novo Nordisk's experimental weight-loss medication CagriSema performed worse than competitor Eli Lilly's Zepbound in a direct comparison study. The disappointing results represent another setback for the Danish pharmaceutical company as it struggles to maintain its position in the rapidly growing obesity treatment market.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771859899456.jpg?fit=450%2C329&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":26201,"url":"https:\/\/tvdelmarva.com\/wp\/experimental-weight-loss-drug-shows-nearly-20-weight-reduction-in-clinical-trial\/","url_meta":{"origin":25466,"position":3},"title":"Experimental Weight Loss Drug Shows Nearly 20% Weight Reduction in Clinical Trial","author":"Admin","date":"February 24, 2026","format":false,"excerpt":"A new obesity medication developed by Novo Nordisk and United Biotechnology demonstrated impressive results in clinical testing, with participants losing nearly 20% of their body weight over six months. The experimental drug targets three different hormone receptors and significantly outperformed placebo treatments in the study.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771927372681.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":32529,"url":"https:\/\/tvdelmarva.com\/wp\/major-drug-companies-rush-to-develop-weight-loss-pills-as-market-shifts\/","url_meta":{"origin":25466,"position":4},"title":"Major Drug Companies Rush to Develop Weight-Loss Pills as Market Shifts","author":"Admin","date":"March 6, 2026","format":false,"excerpt":"The weight-loss medication industry is undergoing major changes as pharmaceutical companies race to create pill versions of popular injectable treatments. With oral alternatives emerging and prices dropping, Wall Street analysts are reconsidering their predictions of a $150 billion market within ten years.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":27781,"url":"https:\/\/tvdelmarva.com\/wp\/new-weight-loss-drug-shows-promise-but-comes-with-more-side-effects\/","url_meta":{"origin":25466,"position":5},"title":"New Weight-Loss Drug Shows Promise But Comes With More Side Effects","author":"Admin","date":"February 26, 2026","format":false,"excerpt":"Pharmaceutical giant Eli Lilly has shared updated findings from a clinical study comparing their experimental weight-loss medication orforglipron against a competitor's drug. The trial revealed that while Lilly's pill achieved better weight loss results, patients experienced more side effects than those taking the rival medication.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1772108275791.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/25466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=25466"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/25466\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/25465"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=25466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=25466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=25466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}